请输入您要查询的百科知识：

　

词条 5-HT2B receptor
释义

  1. Function

  2. Clinical significance

  3. Ligands

     Agonists  Antagonists 

  4. Possible applications

  5. See also

  6. References

  7. Further reading

  8. External links

{{DISPLAYTITLE:5-HT2B receptor}}{{Infobox_gene}}

5-Hydroxytryptamine receptor 2B (5-HT2B) also known as serotonin receptor 2B is a protein that in humans is encoded by the HTR2B gene.[1][2] 5-HT2B is a member of the 5-HT2 receptor family that binds the neurotransmitter serotonin (5-hydroxytryptamine, 5-HT).

Function

The 5-HT2 receptors (of which the 5-HT2B receptor is a subtype) mediate many of the central and peripheral physiologic functions of serotonin. Cardiovascular effects include contraction of blood vessels and shape changes in platelets; central nervous system effects include neuronal sensitization to tactile stimuli and mediation of some of the effects of hallucinogenic substituted amphetamines.

The 5-HT2B receptor subtype is involved in:

  • CNS: presynaptic inhibition, behavioural effects[3]
  • Vascular: pulmonary vasoconstriction[4]
  • Cardiac: The 5-HT2B receptor regulates cardiac structure and functions as demonstrated by the abnormal cardiac development observed in 5-HT2B receptor null mice.[5] The 5-HT2B receptor stimulation can also lead to pathological proliferation of cardiac valves fibroblasts,[6] which with chronic overstimulation of 5-HT2B can lead to a severe valvulopathy. Moreover, 5-HT2B receptors were recently shown to be overexpressed in human failing heart and antagonists of 5-HT2B receptors were uncovered to prevent both angiotensin II or beta-adrenergic agonist-induced pathological cardiac hypertrophy in mouse.[7][8][9]
  • Serotonin transporter: 5-HT2B receptors regulate serotonin release via the serotonin transporter, and are important both to normal physiological regulation of serotonin levels in blood plasma,[10] and with the abnormal acute serotonin release produced by drugs such as MDMA.[3] Surprisingly however 5-HT2B receptor activation appears to be protective against the development of serotonin syndrome following elevated extracellular serotonin levels,[11] despite its role in modulating serotonin release.

Clinical significance

5-HT2B receptors have also been strongly implicated in drug-induced valvular heart disease.[12][13][14] In this context, it is generally considered to be an antitarget.

The structure of the 5-HT2B receptor was recently solved in complex with the valvulopathogenic drug ergotamine.[15]

Ligands

As of 2009, few highly selective 5-HT2B receptor ligands have been discovered, although numerous potent non-selective compounds are known, particularly agents with concomitant 5-HT2C binding. Research in this area has been limited due to the cardiotoxicity of 5-HT2B agonists, and the lack of clear therapeutic application for 5-HT2B antagonists, but there is still a need for selective ligands for scientific research.[16]

Agonists

Selective
  • BW-723C86:[17] fair functional subtype selectivity; almost full agonist. Anxiolytic in vivo.[18]
  • Ro60-0175 [17] functionally selective over 5-HT2A, potent agonist at both 5-HT2B/C
  • VER-3323: selective for 5-HT2B/C over 5-HT2A
  • α-Methyl-5-HT - moderately selective over 5-HT2A/C
  • 6-APB
  • LY-266,097 - biased partial agonist in favor of Gq protein, no β-arrestin2 recruitment[19]
Non-selective
  • Guanfacine - an α2A agonist, but has 5-HT2B agonistic activity at therapeutic concentrations.[20]
  • MDMA[21]
  • MDA[21]
  • MEM[22]
  • Pergolide[23]
  • Cabergoline
  • Norfenfluramine[17]
  • Chlorphentermine
  • Aminorex
  • mCPP
  • Bromo-dragonfly
  • DMT
  • 5-MeO-DMT
  • LSD - About equal affinity for human cloned 5-HT2B and 5-HT2A receptors.[28]
  • psilocin [24]

Antagonists

  • Agomelatine - primarily a melatonin Mt1/Mt2 receptor agonist, with a less potent antagonism of 5-HT2B and 5-HT2C.[25]
  • Amisulpride
  • Aripiprazole
  • Cariprazine[26]
  • Sarpogrelate: a mixed 5-HT2A/B antagonist
  • Lisuride: a dopamine agonist of the ergoline class, that is also a 5-HT2B antagonist[27] and a dual 5-HT2A/C agonist[28]
  • Tegaserod: primarily a 5-HT4 agonist, but also a 5-HT2B antagonist[29]
  • RS-127,445:[30] high affinity; subtype selective (1000x), selective over at least eight other 5-HTR types; orally bioavailable.
  • Metadoxine: a 5ht2b antagonist and GABA-activity modulator [31]
  • SDZ SER-082: a mixed 5-HT2B/C antagonist
  • Promethazine [32]
  • EGIS-7625: high selectivity over 5-HT2A[33]
  • PRX-08066
  • SB-200,646
  • SB-204,741
  • SB-206,553: mixed 5-HT2B/C antagonist and PAM at α7 nAChR[34]
  • SB-215,505 [35]
  • SB-228,357
  • LY-272,015

Possible applications

5-HT2B antagonists have previously been proposed as treatment for migraine headaches, and RS-127,445 was trialled in humans up to Phase I for this indication, but development was not continued.[36] More recent research has focused on possible application of 5-HT2B antagonists as treatments for chronic heart disease.[37][38] Research claims serotonin 5-HT2B receptors have effect on liver regeneration.[39]

See also

  • 5-HT receptor

References

1. ^{{cite web | title = Entrez Gene: HTR2B 5-hydroxytryptamine (serotonin) receptor 2B| url = https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=3357| accessdate = }}
2. ^{{cite journal | vauthors = Schmuck K, Ullmer C, Engels P, Lübbert H | title = Cloning and functional characterization of the human 5-HT2B serotonin receptor | journal = FEBS Letters | volume = 342 | issue = 1 | pages = 85–90 | date = Mar 1994 | pmid = 8143856 | doi = 10.1016/0014-5793(94)80590-3 | url = http://linkinghub.elsevier.com/retrieve/pii/0014-5793(94)80590-3 }}
3. ^1 {{cite journal | vauthors = Doly S, Valjent E, Setola V, Callebert J, Hervé D, Launay JM, Maroteaux L | title = Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro | journal = The Journal of Neuroscience | volume = 28 | issue = 11 | pages = 2933–40 | date = Mar 2008 | pmid = 18337424 | doi = 10.1523/JNEUROSCI.5723-07.2008 }}
4. ^{{cite journal | vauthors = Launay JM, Hervé P, Peoc'h K, Tournois C, Callebert J, Nebigil CG, Etienne N, Drouet L, Humbert M, Simonneau G, Maroteaux L | title = Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension | journal = Nature Medicine | volume = 8 | issue = 10 | pages = 1129–35 | date = Oct 2002 | pmid = 12244304 | doi = 10.1038/nm764 }}
5. ^{{cite journal | vauthors = Nebigil CG, Hickel P, Messaddeq N, Vonesch JL, Douchet MP, Monassier L, György K, Matz R, Andriantsitohaina R, Manivet P, Launay JM, Maroteaux L | title = Ablation of serotonin 5-HT(2B) receptors in mice leads to abnormal cardiac structure and function | journal = Circulation | volume = 103 | issue = 24 | pages = 2973–9 | date = Jun 2001 | pmid = 11413089 | doi = 10.1161/01.cir.103.24.2973 | url = http://circ.ahajournals.org/cgi/content/abstract/103/24/2973 }}
6. ^{{cite journal | vauthors = Elangbam CS, Job LE, Zadrozny LM, Barton JC, Yoon LW, Gates LD, Slocum N | title = 5-hydroxytryptamine (5HT)-induced valvulopathy: compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats | journal = Experimental and Toxicologic Pathology | volume = 60 | issue = 4–5 | pages = 253–62 | date = Aug 2008 | pmid = 18511249 | doi = 10.1016/j.etp.2008.03.005 }}
7. ^{{cite journal | vauthors = Jaffré F, Callebert J, Sarre A, Etienne N, Nebigil CG, Launay JM, Maroteaux L, Monassier L | title = Involvement of the serotonin 5-HT2B receptor in cardiac hypertrophy linked to sympathetic stimulation: control of interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha cytokine production by ventricular fibroblasts | journal = Circulation | volume = 110 | issue = 8 | pages = 969–74 | date = Aug 2004 | pmid = 15302781 | doi = 10.1161/01.CIR.0000139856.20505.57 }}
8. ^{{cite journal | vauthors = Monassier L, Laplante MA, Jaffré F, Bousquet P, Maroteaux L, de Champlain J | title = Serotonin 5-HT(2B) receptor blockade prevents reactive oxygen species-induced cardiac hypertrophy in mice | journal = Hypertension | volume = 52 | issue = 2 | pages = 301–7 | date = Aug 2008 | pmid = 18591460 | doi = 10.1161/HYPERTENSIONAHA.107.105551 }}
9. ^{{cite journal | vauthors = Jaffré F, Bonnin P, Callebert J, Debbabi H, Setola V, Doly S, Monassier L, Mettauer B, Blaxall BC, Launay JM, Maroteaux L | title = Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy | journal = Circulation Research | volume = 104 | issue = 1 | pages = 113–23 | date = Jan 2009 | pmid = 19023134 | doi = 10.1161/CIRCRESAHA.108.180976 }}
10. ^{{cite journal | vauthors = Callebert J, Esteve JM, Hervé P, Peoc'h K, Tournois C, Drouet L, Launay JM, Maroteaux L | title = Evidence for a control of plasma serotonin levels by 5-hydroxytryptamine(2B) receptors in mice | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 317 | issue = 2 | pages = 724–31 | date = May 2006 | pmid = 16461587 | doi = 10.1124/jpet.105.098269 }}
11. ^{{cite journal | vauthors = Diaz SL, Maroteaux L | title = Implication of 5-HT(2B) receptors in the serotonin syndrome | journal = Neuropharmacology | volume = 61 | issue = 3 | pages = 495–502 | date = Sep 2011 | pmid = 21277875 | doi = 10.1016/j.neuropharm.2011.01.025 | url = http://www.hal.inserm.fr/inserm-00561473 }}
12. ^{{cite journal | vauthors = Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL | title = Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications | journal = Circulation | volume = 102 | issue = 23 | pages = 2836–41 | date = Dec 2000 | pmid = 11104741 | doi = 10.1161/01.CIR.102.23.2836 }}
13. ^{{cite journal | vauthors = Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JR, Abbaszade I, Hollis JM, Largent BL, Hartig PR, Hollis GF, Meunier PC, Robichaud AJ, Robertson DW | title = Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine | journal = Molecular Pharmacology | volume = 57 | issue = 1 | pages = 75–81 | date = Jan 2000 | pmid = 10617681 | doi = }}
14. ^{{cite journal | vauthors = Roth BL | title = Drugs and valvular heart disease | journal = The New England Journal of Medicine | volume = 356 | issue = 1 | pages = 6–9 | date = Jan 2007 | pmid = 17202450 | doi = 10.1056/NEJMp068265 }}
15. ^{{PDB|4IB4}}; {{cite journal | vauthors = Wacker D, Wang C, Katritch V, Han GW, Huang XP, Vardy E, McCorvy JD, Jiang Y, Chu M, Siu FY, Liu W, Xu HE, Cherezov V, Roth BL, Stevens RC | title = Structural features for functional selectivity at serotonin receptors | journal = Science | volume = 340 | issue = 6132 | pages = 615–9 | date = May 2013 | pmid = 23519215 | doi = 10.1126/science.1232808 | pmc=3644390| bibcode = 2013Sci...340..615W }}
16. ^{{cite journal | author = Schuhmacher M | title = [Chiral arylmethoxytryptamines as 5-HT2B-receptor antagonists: synthesis, analysis and in-vitro pharmacology] (German) | version = Ph.D. Dissertation | publisher = University of Regensburg | year = 2007 | pages = 6–17 | url = http://www.opus-bayern.de/uni-regensburg/volltexte/2008/796/pdf/Dissertation_Schumacher.pdf | accessdate = 2008-08-11 }}
17. ^1 2 {{cite journal | vauthors = Porter RH, Benwell KR, Lamb H, Malcolm CS, Allen NH, Revell DF, Adams DR, Sheardown MJ | title = Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells | journal = British Journal of Pharmacology | volume = 128 | issue = 1 | pages = 13–20 | date = Sep 1999 | pmid = 10498829 | pmc = 1571597 | doi = 10.1038/sj.bjp.0702751 }}
18. ^{{cite journal | vauthors = Kennett GA, Trail B, Bright F | title = Anxiolytic-like actions of BW 723C86 in the rat Vogel conflict test are 5-HT2B receptor mediated | journal = Neuropharmacology | volume = 37 | issue = 12 | pages = 1603–10 | date = Dec 1998 | pmid = 9886683 | doi = 10.1016/S0028-3908(98)00115-4 }}
19. ^{{cite journal | vauthors = McCorvy JD, Wacker D, Wang S, Agegnehu B, Liu J, Lansu K, Tribo AR, Olsen RH, Che T, Jin J, Roth BL | display-authors = 6 | title = Structural determinants of 5-HT2B receptor activation and biased agonism | journal = Nature Structural & Molecular Biology | volume = 25| issue = 9| pages = 787–796 | date = August 2018 | pmid = 30127358 | pmc = 6237183 | doi = 10.1038/s41594-018-0116-7 }}
20. ^{{cite journal | vauthors = Huang XP, Setola V, Yadav PN, Allen JA, Rogan SC, Hanson BJ, Revankar C, Robers M, Doucette C, Roth BL | title = Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment | journal = Molecular Pharmacology | volume = 76 | issue = 4 | date = Oct 2009 | pmid = 19570945 | doi = 10.1124/mol.109.058057 | pmc=2769050 | pages=710–22}}
21. ^1 {{cite journal | vauthors = Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL | author3link=Jane Grande-Allen | title = 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro | journal = Molecular Pharmacology | volume = 63 | issue = 6 | pages = 1223–1229 | date = Jun 2003 | pmid = 12761331 | doi = 10.1124/mol.63.6.1223 | url = https://www.researchgate.net/publication/10748715 }}
22. ^{{cite journal | vauthors = Ray TS | title = Psychedelics and the human receptorome | journal = PLOS ONE | volume = 5 | issue = 2 | pages = e9019 | year = 2010 | pmid = 20126400 | pmc = 2814854 | doi = 10.1371/journal.pone.0009019 | editor1-last = Manzoni | editor1-first = Olivier Jacques | name-list-format = vanc | bibcode = 2010PLoSO...5.9019R }}
23. ^{{cite journal | vauthors = Görnemann T, Hübner H, Gmeiner P, Horowski R, Latté KP, Flieger M, Pertz HH | title = Characterization of the molecular fragment that is responsible for agonism of pergolide at serotonin 5-Hydroxytryptamine2B and 5-Hydroxytryptamine2A receptors | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 324 | issue = 3 | pages = 1136–45 | date = Mar 2008 | pmid = 18096760 | doi = 10.1124/jpet.107.133165 }}
24. ^1 PDSP Ki database, University of North Carolina at Chapel Hill. {{cite web|url=http://pdsp.med.unc.edu/pdsp.php |title=Archived copy |accessdate=2014-03-04 |deadurl=yes |archiveurl=https://web.archive.org/web/20131108013656/http://pdsp.med.unc.edu/pdsp.php |archivedate=2013-11-08 |df= }}
25. ^{{cite journal | vauthors = Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, Rivet JM, Cussac D | title = The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 306 | issue = 3 | pages = 954–64 | date = Sep 2003 | pmid = 12750432 | doi = 10.1124/jpet.103.051797 }}
26. ^{{Cite journal|last=Garnock-Jones|first=Karly P.|date=June 2017|title=Cariprazine: A Review in Schizophrenia|journal=CNS Drugs|volume=31|issue=6|pages=513–525|doi=10.1007/s40263-017-0442-z|issn=1179-1934|pmid=28560619}}
27. ^{{cite journal | vauthors = Hofmann C, Penner U, Dorow R, Pertz HH, Jähnichen S, Horowski R, Latté KP, Palla D, Schurad B | title = Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis | journal = Clinical Neuropharmacology | volume = 29 | issue = 2 | pages = 80–6 | year = 2006 | pmid = 16614540 | doi = 10.1097/00002826-200603000-00005 | url = http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?an=00002826-200603000-00005 }}
28. ^{{cite journal | vauthors = Egan CT, Herrick-Davis K, Miller K, Glennon RA, Teitler M | title = Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors | journal = Psychopharmacology | volume = 136 | issue = 4 | pages = 409–14 | date = Apr 1998 | pmid = 9600588 | doi = 10.1007/s002130050585 }}
29. ^{{cite journal | vauthors = Beattie DT, Smith JA, Marquess D, Vickery RG, Armstrong SR, Pulido-Rios T, McCullough JL, Sandlund C, Richardson C, Mai N, Humphrey PP | title = The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo | journal = British Journal of Pharmacology | volume = 143 | issue = 5 | pages = 549–60 | date = Nov 2004 | pmid = 15466450 | pmc = 1575425 | doi = 10.1038/sj.bjp.0705929 }}
30. ^{{cite journal | vauthors = Bonhaus DW, Flippin LA, Greenhouse RJ, Jaime S, Rocha C, Dawson M, Van Natta K, Chang LK, Pulido-Rios T, Webber A, Leung E, Eglen RM, Martin GR | title = RS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist | journal = British Journal of Pharmacology | volume = 127 | issue = 5 | pages = 1075–82 | date = Jul 1999 | pmid = 10455251 | pmc = 1566110 | doi = 10.1038/sj.bjp.0702632 }}
31. ^{{cite web|url=http://www.alcobra-pharma.com/products.cfm?productID=142236 |title=Metadoxine extended release (MDX) for adult ADHD|publisher=Alcobra Ltd|date=2014|accessdate=2014-05-07}}
32. ^{{Cite web|url=http://www.guidetopharmacology.org/GRAC/LigandActivityRangeVisForward?ligandId=7282|title=promethazine {{!}} Activity data visualisation tool {{!}} IUPHAR/BPS Guide to PHARMACOLOGY|website=www.guidetopharmacology.org|access-date=2019-02-28}}
33. ^{{cite journal | vauthors = Kovács A, Gacsályi I, Wellmann J, Schmidt E, Szücs Z, Dubreuil V, Nicolas JP, Boutin J, Bózsing D, Egyed A, Tihanyi K, Spedding M, Szénási G | title = Effects of EGIS-7625, a selective and competitive 5-HT2B receptor antagonist | journal = Cardiovascular Drugs and Therapy / Sponsored by the International Society of Cardiovascular Pharmacotherapy | volume = 17 | issue = 5–6 | pages = 427–34 | year = 2003 | pmid = 15107597 | doi = 10.1023/B:CARD.0000015857.96371.43 }}
34. ^{{cite journal | vauthors = Dunlop J, Lock T, Jow B, Sitzia F, Grauer S, Jow F, Kramer A, Bowlby MR, Randall A, Kowal D, Gilbert A, Comery TA, Larocque J, Soloveva V, Brown J, Roncarati R | title = Old and new pharmacology: positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor by the 5-hydroxytryptamine(2B/C) receptor antagonist SB-206553 (3,5-dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b:4,5-b']di pyrrole-1(2H)-carboxamide) | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 328 | issue = 3 | pages = 766–76 | date = Mar 2009 | pmid = 19050173 | doi = 10.1124/jpet.108.146514 }}
35. ^{{cite journal | vauthors = Reavill C, Kettle A, Holland V, Riley G, Blackburn TP | title = Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist | journal = British Journal of Pharmacology | volume = 126 | issue = 3 | pages = 572–4 | date = Feb 1999 | pmid = 10188965 | pmc = 1565856 | doi = 10.1038/sj.bjp.0702350 }}
36. ^{{cite journal | vauthors = Poissonnet G, Parmentier JG, Boutin JA, Goldstein S | title = The emergence of selective 5-HT 2B antagonists structures, activities and potential therapeutic applications | journal = Mini Reviews in Medicinal Chemistry | volume = 4 | issue = 3 | pages = 325–30 | date = Mar 2004 | pmid = 15032678 | doi = 10.2174/1389557043487312 }}
37. ^{{cite journal | vauthors = Shyu KG | title = Serotonin 5-HT2B receptor in cardiac fibroblast contributes to cardiac hypertrophy: a new therapeutic target for heart failure? | journal = Circulation Research | volume = 104 | issue = 1 | pages = 1–3 | date = Jan 2009 | pmid = 19118279 | doi = 10.1161/CIRCRESAHA.108.191122 }}
38. ^{{cite journal | vauthors = Moss N, Choi Y, Cogan D, Flegg A, Kahrs A, Loke P, Meyn O, Nagaraja R, Napier S, Parker A, Thomas Peterson J, Ramsden P, Sarko C, Skow D, Tomlinson J, Tye H, Whitaker M | title = A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties | journal = Bioorganic & Medicinal Chemistry Letters | volume = 19 | issue = 8 | pages = 2206–10 | date = Apr 2009 | pmid = 19307114 | doi = 10.1016/j.bmcl.2009.02.126 }}
39. ^{{cite journal | vauthors = Ebrahimkhani MR, Oakley F, Murphy LB, Mann J, Moles A, Perugorria MJ, Ellis E, Lakey AF, Burt AD, Douglass A, Wright MC, White SA, Jaffré F, Maroteaux L, Mann DA | title = Stimulating healthy tissue regeneration by targeting the 5-HT₂B receptor in chronic liver disease | journal = Nature Medicine | volume = 17 | issue = 12 | pages = 1668–73 | date = Dec 2011 | pmid = 22120177 | pmc = 3428919 | doi = 10.1038/nm.2490 }}

Further reading

{{refbegin|colwidth=33em}}
  • {{cite journal | vauthors = Raymond JR, Mukhin YV, Gelasco A, Turner J, Collinsworth G, Gettys TW, Grewal JS, Garnovskaya MN | title = Multiplicity of mechanisms of serotonin receptor signal transduction | journal = Pharmacology & Therapeutics | volume = 92 | issue = 2–3 | pages = 179–212 | year = 2002 | pmid = 11916537 | doi = 10.1016/S0163-7258(01)00169-3 }}
  • {{cite journal | vauthors = Bonhaus DW, Bach C, DeSouza A, Salazar FH, Matsuoka BD, Zuppan P, Chan HW, Eglen RM | title = The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors | journal = British Journal of Pharmacology | volume = 115 | issue = 4 | pages = 622–8 | date = Jun 1995 | pmid = 7582481 | pmc = 1908489 | doi = 10.1111/j.1476-5381.1995.tb14977.x }}
  • {{cite journal | vauthors = Choi DS, Birraux G, Launay JM, Maroteaux L | title = The human serotonin 5-HT2B receptor: pharmacological link between 5-HT2 and 5-HT1D receptors | journal = FEBS Letters | volume = 352 | issue = 3 | pages = 393–9 | date = Oct 1994 | pmid = 7926008 | doi = 10.1016/0014-5793(94)00968-6 }}
  • {{cite journal | vauthors = Kursar JD, Nelson DL, Wainscott DB, Baez M | title = Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine2B receptor | journal = Molecular Pharmacology | volume = 46 | issue = 2 | pages = 227–34 | date = Aug 1994 | pmid = 8078486 | doi = }}
  • {{cite journal | vauthors = Schmuck K, Ullmer C, Engels P, Lübbert H | title = Cloning and functional characterization of the human 5-HT2B serotonin receptor | journal = FEBS Letters | volume = 342 | issue = 1 | pages = 85–90 | date = Mar 1994 | pmid = 8143856 | doi = 10.1016/0014-5793(94)80590-3 }}
  • {{cite journal | vauthors = Launay JM, Birraux G, Bondoux D, Callebert J, Choi DS, Loric S, Maroteaux L | title = Ras involvement in signal transduction by the serotonin 5-HT2B receptor | journal = The Journal of Biological Chemistry | volume = 271 | issue = 6 | pages = 3141–7 | date = Feb 1996 | pmid = 8621713 | doi = 10.1074/jbc.271.6.3141 }}
  • {{cite journal | vauthors = Le Coniat M, Choi DS, Maroteaux L, Launay JM, Berger R | title = The 5-HT2B receptor gene maps to 2q36.3-2q37.1 | journal = Genomics | volume = 32 | issue = 1 | pages = 172–3 | date = Feb 1996 | pmid = 8786115 | doi = 10.1006/geno.1996.0101 }}
  • {{cite journal | vauthors = Kim SJ, Veenstra-VanderWeele J, Hanna GL, Gonen D, Leventhal BL, Cook EH | title = Mutation screening of human 5-HT(2B)receptor gene in early-onset obsessive-compulsive disorder | journal = Molecular and Cellular Probes | volume = 14 | issue = 1 | pages = 47–52 | date = Feb 2000 | pmid = 10722792 | doi = 10.1006/mcpr.1999.0281 }}
  • {{cite journal | vauthors = Manivet P, Mouillet-Richard S, Callebert J, Nebigil CG, Maroteaux L, Hosoda S, Kellermann O, Launay JM | title = PDZ-dependent activation of nitric-oxide synthases by the serotonin 2B receptor | journal = The Journal of Biological Chemistry | volume = 275 | issue = 13 | pages = 9324–31 | date = Mar 2000 | pmid = 10734074 | doi = 10.1074/jbc.275.13.9324 }}
  • {{cite journal | vauthors = Becamel C, Figge A, Poliak S, Dumuis A, Peles E, Bockaert J, Lubbert H, Ullmer C | title = Interaction of serotonin 5-hydroxytryptamine type 2C receptors with PDZ10 of the multi-PDZ domain protein MUPP1 | journal = The Journal of Biological Chemistry | volume = 276 | issue = 16 | pages = 12974–82 | date = Apr 2001 | pmid = 11150294 | doi = 10.1074/jbc.M008089200 }}
  • {{cite journal | vauthors = Manivet P, Schneider B, Smith JC, Choi DS, Maroteaux L, Kellermann O, Launay JM | title = The serotonin binding site of human and murine 5-HT2B receptors: molecular modeling and site-directed mutagenesis | journal = The Journal of Biological Chemistry | volume = 277 | issue = 19 | pages = 17170–8 | date = May 2002 | pmid = 11859080 | doi = 10.1074/jbc.M200195200 }}
  • {{cite journal | vauthors = Borman RA, Tilford NS, Harmer DW, Day N, Ellis ES, Sheldrick RL, Carey J, Coleman RA, Baxter GS | title = 5-HT(2B) receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro | journal = British Journal of Pharmacology | volume = 135 | issue = 5 | pages = 1144–51 | date = Mar 2002 | pmid = 11877320 | pmc = 1573235 | doi = 10.1038/sj.bjp.0704571 }}
  • {{cite journal | vauthors = Matsuda A, Suzuki Y, Honda G, Muramatsu S, Matsuzaki O, Nagano Y, Doi T, Shimotohno K, Harada T, Nishida E, Hayashi H, Sugano S | title = Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways | journal = Oncogene | volume = 22 | issue = 21 | pages = 3307–18 | date = May 2003 | pmid = 12761501 | doi = 10.1038/sj.onc.1206406 }}
  • {{cite journal | vauthors = Slominski A, Pisarchik A, Zbytek B, Tobin DJ, Kauser S, Wortsman J | title = Functional activity of serotoninergic and melatoninergic systems expressed in the skin | journal = Journal of Cellular Physiology | volume = 196 | issue = 1 | pages = 144–53 | date = Jul 2003 | pmid = 12767050 | doi = 10.1002/jcp.10287 }}
  • {{cite journal | vauthors = Lin Z, Walther D, Yu XY, Drgon T, Uhl GR | title = The human serotonin receptor 2B: coding region polymorphisms and association with vulnerability to illegal drug abuse | journal = Pharmacogenetics | volume = 14 | issue = 12 | pages = 805–11 | date = Dec 2004 | pmid = 15608559 | doi = 10.1097/00008571-200412000-00003 }}
{{refend}}

External links

  • {{cite web | url = http://www.iuphar-db.org/GPCR/ReceptorDisplayForward?receptorID=2322 | title = 5-HT2B | accessdate = | author = | authorlink = | format = | work = IUPHAR Database of Receptors and Ion Channels | publisher = International Union of Basic and Clinical Pharmacology | pages = | quote = }}
  • {{UCSC gene info|HTR2B}}
{{NLM content}}{{G protein-coupled receptors|g1}}{{Cell signaling}}{{Serotonergics}}{{DEFAULTSORT:5-Ht2b Receptor}}

1 : Serotonin receptors
随便看

　

开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。

　

Copyright © 2023 OENC.NET All Rights Reserved
京ICP备2021023879号 更新时间：2024/9/22 15:34:42